Literature DB >> 6821809

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.

A Lipton, H A Harvey, B Lawrence, R Gottlieb, M Kukrika, R Dixon, W Graham, S Miller, R Heckard, D Schelzel, D S White.   

Abstract

One-hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette-Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs-Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients treated with C. parvum.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6821809     DOI： 10.1002/1097-0142(19830101)51:1<57::aid-cncr2820510114>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  9 in total

1.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

Review 2.  Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy.

Authors:  Eytan Ben-Ami; Jacob Schachter
Journal:  Melanoma Manag       Date:  2016-05-25

Review 3.  Need for immunologic stimulators during immunosuppression produced by major cancer surgery.

Authors:  W H Cole; L Humphrey
Journal:  Ann Surg       Date:  1985-07       Impact factor: 12.969

Review 4.  Current treatment options for malignant melanoma.

Authors:  G L Cohen; C I Falkson
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

5.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

Review 6.  Melanoma: adjuvant therapy and other treatment options.

Authors:  Alicia Terando; Michael S Sabel; Vernon K Sondak
Journal:  Curr Treat Options Oncol       Date:  2003-06

7.  COVID-19 vaccine and boosted immunity: Nothing ad interim to do?

Authors:  Luca Roncati; Maria Vadalà; Veronica Corazzari; Beniamino Palmieri
Journal:  Vaccine       Date:  2020-10-09       Impact factor: 3.641

8.  Dysbiosis of skin microbiome and gut microbiome in melanoma progression.

Authors:  Chahrazed Mekadim; Helena Kupcova Skalnikova; Jana Cizkova; Veronika Cizkova; Anna Palanova; Vratislav Horak; Jakub Mrazek
Journal:  BMC Microbiol       Date:  2022-02-25       Impact factor: 3.605

9.  Killed Propionibacterium acnes enhances immunogenicity and tumor growth control of a dendritic-tumor cell hybrid vaccine in a murine melanoma model.

Authors:  Mayari E Ishimura; Daniela Teixeira; Gabriela da P Silveira; Mônica Gambero; Gabriel A C Gama; Bruna S O Pimenta; Elaine G Rodrigues; Ieda M Longo-Maugéri
Journal:  PLoS One       Date:  2018-10-09       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.